Betopharm and Inge Biologics Announce Strategic Partnership to Strengthen CDMO Technology Platform

SuzhouFebruary 21, 2023PR Newswire -- February 20, 2023, Porton Biologics Ltd. (hereinafter referred to as "Porton Biologics") announced a strategic partnership with YINJIA BIOSCIENCES (hereinafter referred to as "YINJIA BIOSCIENCES"). The two parties have established a strategic cooperative relationship in the development of core protein raw materials for gene and cell therapy, as well as the development of quality control and evaluation system testing reagents, accelerating the development and commercialization process of gene and cell therapy.

Porton Biologics Ltd. is committed to providing end-to-end gene and cell therapy CDMO services, covering businesses such as plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapy, and live bacterial therapies. YINJIA BIOSCIENCES focuses on high-barrier core protein raw materials while actively developing companion diagnostic products that support innovative therapies which have matured in recent years. According to the agreement, YINJIA BIOSCIENCES will provide Porton Biologics with high-quality core key protein raw materials and testing reagent product services related to quality control and evaluation systems. Both parties will work together to promote the research, development, and industrialization of gene and cell therapy drugs. In the future, Porton Biologics will continue to strengthen its technical platform construction, improve end-to-end CDMO platform capabilities, and drive the rapid development of the CGT industry to meet clinical needs and empower global partners.

Dr. Wang Yangzhou, CEO of Porton Biologics Ltd., stated: "We are very pleased to reach a strategic cooperation with YINJIA BIOSCIENCES. YINJIA BIOSCIENCES possesses a powerful high-end protein R&D technology platform and has rich industry experience and technical advantages in core critical protein raw materials and testing reagents. Through this strategic cooperation, the two parties will join hands to further enhance the comprehensive strength of Porton Biologics' gene and cell therapy CDMO platform, accelerate the development of innovative CGT drugs, address patients' medication needs, and make quality medicines available to the public as soon as possible."

Dr. Wu Yifei, Chairman and CEO of YINJIA BIOSCIENCES, stated: "Porton Biologics Ltd., as an advanced CDMO platform in the gene and cell therapy field, has a business level and coverage that are recognized industry-wide, providing a strong complement to the biopharmaceutical industry’s supply chain and offering robust support for drug research and development transformation. As a protein technology platform company, this strategic cooperation between YINJIA BIOSCIENCES and Porton Biologics will further expand product application areas and technical directions, addressing a broader range of customer needs."